Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of DN1508052-01 in Advanced Solid Tumors
NCT03934359Phase 1Completed
- Sponsor
- Shanghai De Novo Pharmatech
- Start
- Sep 2019
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DN1508052 in solid tumor (advanced stage), sponsored by Shanghai De Novo Pharmatech. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Phase 2 Dose at 28 days and 1 more. Started Sep 2019; status: completed.
02
Drugs
DN1508052
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03934359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03934359.